Explore

Upadacitinib, an Arthritis Drug, Shows Promise for Hair Regrowth in Alopecia Patients

Upadacitinib, an Arthritis Drug, Shows Promise for Hair Regrowth in Alopecia Patients

Two international Phase III clinical trials have demonstrated that upadacitinib, a medication typically used for rheumatoid arthritis, is effective in promoting hair regrowth in individuals suffering from alopecia areata. Alopecia areata is an autoimmune disease where the immune system attacks hair follicles, leading to hair loss. The trials, UP-AA1 and UP-AA2, involved 1,399 participants, including adolescents aged 12 to 17 and adults up to 64, all with at least 50% scalp hair loss. Participants were randomly assigned to receive either a 15 mg daily dose of upadacitinib, a 30 mg daily dose, or a placebo. The results, published in JAMA Dermatology, indicated that nearly half of those on the 15 mg dose achieved 80% or more scalp-hair coverage within 24 weeks, while over 54% on the 30 mg dose reached this milestone. In contrast, only about 2% of the placebo group experienced similar regrowth. Beyond scalp hair, patients also reported improvements in eyebrow and eyelash regrowth, alongside enhanced emotional ...

Dermatologist Advises Caution on Topical Isotretinoin for Acne Treatment

Dermatologist Advises Caution on Topical Isotretinoin for Acne Treatment

Dr. John Barbieri, Director of the advanced acne therapeutics clinic at Brigham and Women’s Hospital, advises against the use of topical isotretinoin for acne treatment, particularly for teenagers. Despite its marketing as an alternative to oral isotretinoin, clinical trials indicate that topical isotretinoin does not outperform other established topical retinoids like adapalene or tretinoin. Furthermore, topical isotretinoin is not an FDA-licensed product in the United States and must be compounded. This compounding process introduces potential risks due to less regulated quality controls compared to products available through regular pharmacies. Dr. Barbieri emphasizes that there is no scenario where he would consider topical isotretinoin superior to other over-the-counter (OTC) options.

AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED have reported positive high-level results from the SAFFRON Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with savolitinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This trial focused on patients whose tumors exhibited high levels of MET overexpression or amplification and had progressed after prior treatment with TAGRISSO. MET-driven resistance is a common mechanism of progression in EGFRm NSCLC patients treated with third-generation EGFR-tyrosine kinase inhibitors (TKIs), often leading to poor prognosis and a lack of effective, well-tolerated treatment options. The safety profile of the combination therapy was consistent with the known profiles of each medicine, with no new safety findings observed. These findings reinforce TAGRISSO as a foundational therapy in EGFRm lung cancer and highlight the potential of this novel ...

Japanese Research Team Awarded $1 Million in XPRIZE Healthspan Competition for 'Super Exosomes'

Japanese Research Team Awarded $1 Million in XPRIZE Healthspan Competition for 'Super Exosomes'

A research team from Tohoku University and the University of Tokyo, led by Professor Keisuke Goda, has been named a Milestone 2 Awardee in the XPRIZE Healthspan competition, receiving a $1 million award. This global competition, spanning seven years, aims to incentivize the development of therapeutics that can restore muscle, cognition, and immune function in adults aged 50 to 90, with a goal of extending healthy life by 10 to 20 years within a year of treatment. The Japanese team's groundbreaking research focuses on 'super exosomes,' which are tiny natural particles chemically engineered with lanthanide ions to enhance their ability to target senescent cells. Senescent cells are aged or damaged cells that cease dividing but remain in the body, contributing to aging and age-related diseases. These super exosomes efficiently deliver regenerative molecular cargo, such as growth factors or genetic material, directly to aging tissues to promote repair.

Shorter Antibiotic Courses Found Effective, Challenging Long-Standing Medical Advice

Shorter Antibiotic Courses Found Effective, Challenging Long-Standing Medical Advice

A review of over 120 randomized controlled trials has revealed that shorter courses of antibiotics for common infections can be as effective and safer than longer courses, while also being no more likely to promote antibiotic resistance. This finding challenges the long-held medical advice, prevalent since the 1940s, that patients must always complete their full course of antibiotics. Experts, including population health researcher Alistair Thorpe of the University of Utah, indicate that unnecessary prolonged exposure to antibiotics might actually contribute to the problem of antibiotic resistance. The study, published in Open Forum Infectious Diseases, surveyed 1,475 U.S. respondents, finding that a majority (892) preferred longer courses, often due to prior medical advice and a belief that longer treatments are inherently better. However, many respondents (58.4 percent) expressed comfort with the idea of stopping antibiotics when feeling better, if advised by their clinician.

FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

The U.S. Food and Drug Administration (FDA) has released draft guidance titled 'Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.' This guidance aims to adapt the regulatory approval process for individualized genetic interventions, particularly for rare genetic disorders affecting a small number of patients. Traditionally, each variant-specific modification would require its own investigational new drug application (IND) and extensive testing, which is economically and logistically infeasible for 'n-of-1' or 'n-of-few' patient populations. The new framework outlines five key elements for approval: a specific genetic abnormality with a clear link to disease, a therapy targeting the underlying pathology, a well-characterized natural history of the disease, confirmation of successful targeting, and demonstrated improvement in clinical outcomes. The draft guidance provides more detail on nonc...

American Hospital Association Urges CMS to Mandate Prospective Drug Pricing for Medicare Negotiation Program

American Hospital Association Urges CMS to Mandate Prospective Drug Pricing for Medicare Negotiation Program

The American Hospital Association (AHA) has submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding its proposed rule for the Medicare Drug Price Negotiation Program (MDPNP) and Medicare Prescription Drug Benefit Program. While supporting CMS's goal of lowering prescription drug costs for Medicare beneficiaries, the AHA is advocating for a specific implementation approach. The AHA urges CMS to require drug manufacturers to make the Maximum Fair Price (MFP) available through a prospective, point-of-sale mechanism. This means the discounted price would be applied at the time of sale, rather than through retrospective rebates or post-sale reconciliations. The AHA believes this approach is crucial to ensure successful implementation, avoid unintended consequences for hospitals and the 340B program, and reduce administrative burdens. The proposed rule aims to codify the drug pricing provisions of the Inflation Reduction Act (IRA) of 2022.

Organizations Urge CMS to Enhance Patient Engagement and Access in Medicare Drug Price Negotiation Program

Organizations Urge CMS to Enhance Patient Engagement and Access in Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services (CMS) has proposed a rule to codify the Medicare Drug Price Negotiation Program, prompting various organizations to submit comments advocating for improvements. The HIV+Hepatitis Policy Institute is urging CMS to implement mandatory patient engagement, transparently account for patient input, and establish limits on utilization management and tier gaming for selected drugs. Families USA strongly supports the codification but emphasizes the need to reinstate a comprehensive public list of drugs eligible for negotiation, close loopholes that allow companies to evade negotiation, and reject the use of therapeutic alternative prices as a starting point for fair pricing. The American Hospital Association (AHA) recommends that CMS require drug manufacturers to make the maximum fair price available at the point of sale and eliminate retrospective rebates. Patients Rising supports Medicare's authority to negotiate drug prices but stresses that the savings must directly ...

Gamgee Launches Personalized mRNA Cancer Vaccines for Dogs, Aims for Cross-Species Application

Gamgee Launches Personalized mRNA Cancer Vaccines for Dogs, Aims for Cross-Species Application

Gamgee, a new biotechnology company, has launched with $4 million in seed funding to develop personalized mRNA cancer vaccines for dogs. The company's approach involves sequencing each dog's tumor to identify unique, tumor-specific neoantigens. These neoantigens are then encoded into an mRNA vaccine, designed to train the dog's immune system to recognize and attack its specific cancer. This initiative was inspired by the founder, Paul Conyngham, who developed a personalized treatment for his own rescue dog, Rosie, after traditional therapies failed. Rosie's treatment, which involved genomics, AI, and mRNA technology, laid the groundwork for Gamgee's platform. Clinical studies for these personalized vaccines are currently underway in Australia, with the company working to establish the appropriate regulatory pathways for patient-specific veterinary biologics in the U.S. Gamgee's long-term vision extends beyond veterinary medicine, aiming to make personalized mRNA vaccines accessible through veterinary oncol...

What Dandruff Treatment Actually Looks Like When Done Right

What Dandruff Treatment Actually Looks Like When Done Right

Tired of flakes? Learn the right way to treat dandruff, from choosing the correct ingredients to proper washing techniques for a healthy scalp.

Former Media Executive Alex Taylor Launches Women's Health Supplement Brand After Autoimmune Diagnosis

Former Media Executive Alex Taylor Launches Women's Health Supplement Brand After Autoimmune Diagnosis

You want to join a clinical trial. What to know about the hurdles

You want to join a clinical trial. What to know about the hurdles

HHS began an effort to streamline clinical research, and legislation is pending in Congress. But patients and providers face participation challenges.